BIO VITOS PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.185 SEK | -4.64% |
|
-15.53% | -22.27% |
| Sales 2022 | 4.74M 433K | Sales 2023 | 3M 274K | Capitalization | 8.18M 748K |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.28M | Net income 2023 | -12M -1.1M | EV / Sales 2022 | 0.7 x |
| Net cash position 2022 | 3.19M 291K | Net cash position 2023 | 3.07M 281K | EV / Sales 2023 | 1.7 x |
| P/E ratio 2022 |
-0.33
x | P/E ratio 2023 |
-1.04
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 7.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.64% | ||
| 1 week | -15.53% | ||
| Current month | -11.90% | ||
| 1 month | -12.32% | ||
| 3 months | +13.85% | ||
| 6 months | +35.53% | ||
| Current year | -22.27% |
1 week
0.18
0.24
1 month
0.180.25
Current year
0.140.28
1 year
0.080.49
3 years
0.083.90
5 years
0.087.64
10 years
0.0817.60
| Managers | Title | Age | Since |
|---|---|---|---|
Joen Averstad
CEO | Chief Executive Officer | 40 | 11-12-31 |
Robert Thorén
DFI | Director of Finance/CFO | 47 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 50 | 09-12-31 | |
| Founder | 52 | 09-12-31 | |
| Director/Board Member | 65 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.185 | -4.64% | 70,615 |
| 24-04-25 | 0.194 | -0.77% | 402,000 |
| 24-04-24 | 0.1955 | +2.89% | 2,179 |
| 24-04-23 | 0.19 | -8.21% | 160,167 |
| 24-04-22 | 0.207 | -5.48% | 240,817 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:20 am EDT
More quotes
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.27% | 4.96M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- BIOVIT Stock
